Myopia, or nearsightedness, is becoming more common in children around the world. As a child’s eye grows, the eyeball can elongate too much, causing light to focus in front of the retina instead of directly on it. This results in blurry distance vision and puts children at risk of developing high myopia—a more serious form of nearsightedness. High myopia can increase the risk of long-term eye health problems, including retinal detachment, glaucoma, and cataracts.¹
Because children’s eyes grow rapidly, the progression of myopia during the school years is a serious concern. Slowing that progression is a major goal for optometrists and parents alike, and until recent innovations, options for myopia control were limited.
Introducing Essilor® Stellest®: A Breakthrough in Myopia Management
Enter Essilor® Stellest® lenses, a groundbreaking solution designed specifically to help slow myopia progression in children. This isn’t just another corrective lens—it’s the first and only spectacle lens in the U.S. that’s FDA market-authorized for slowing myopia in children, making it a true medical-device innovation.²
On September 25, 2025, the U.S. Food and Drug Administration granted market authorization for the Stellest lens through its De Novo pathway. This followed the lens’s earlier designation as a “Breakthrough Device” in 2021 due to its promise in helping address childhood myopia.³
How Do Stellest Lenses Work?
The magic lies in Stellest’s unique optical design, powered by something Essilor calls HALT™ technology (Highly Aspherical Lenslet Target). Rather than being a simple flat lens, each Stellest lens includes a central clear zone about 9 mm in diameter, surrounded by multiple concentric rings of tiny, raised dots (or “lenslets”).⁴
These lenslets act by creating a “myopic defocus”—a clever trick that subtly changes how light is focused in the peripheral retina (the outer edge of the eye). This defocus sends a signal to the eye to slow its axial growth, helping to curb how quickly nearsightedness advances. Think of it as a gentle nudge, telling the eye: “No rush—take your time growing.”⁴
Clinical Proof: What the Research Shows
The efficacy of Stellest isn’t just theoretical. Clinical data is strong and compelling:
- Over a two-year U.S. clinical study, children wearing Stellest lenses saw an average 71% reduction in myopia progression compared to children wearing standard single-vision lenses.²
- The same study also demonstrated a 53% slowing of eye elongation, which is critical because the eye’s axial length is directly linked to myopia risk.²
- Long-term data is also promising. A four-year study presented at the 2023 ARVO meeting showed that Stellest lenses saved more than 1.25 diopters of myopia on average.⁶
- Even more impressive: according to six-year data announced in 2025, children who wore Stellest lenses experienced a 57% reduction in myopia progression vs. an extrapolated single-vision control group, and an average eye elongation slowdown of 52%.⁵
Why Stellest Matters for Parents and Eye Care Providers
- Early and safe intervention
Because Stellest is now FDA-authorized, it offers a safer, non-invasive option for children as young as 6. Unlike contact lenses, which can carry a risk of infection or require more maintenance, these are simply worn like regular eyeglasses.² - Long-term eye health
Slowing myopia progression isn’t just about fewer prescriptions—it’s about reducing the risk of serious eye conditions later in life.⁵ - Consistency pays off
Clinical results showed greater benefits when lenses were worn for 12+ hours a day, so encouraging consistent wear can make a big difference.⁸ - Adaptation is fast
According to Essilor, 100% of children adapted fully to Stellest lenses within a week, even though the lens design is more complex than standard glasses.⁸
Things to Consider & Possible Side Effects
While Stellest lenses are generally very well tolerated, a few children in clinical studies reported mild visual symptoms like blur or halos, particularly in early adaptation.² These side effects tended to be temporary, and there were no serious adverse events.²
As with any myopia management strategy, it’s essential for parents to choose a qualified eyecare professional who understands myopia control. The effectiveness of Stellest—or any myopia-slowing lens—depends on proper prescription, consistent wear, and regular follow-up visits.
Looking Ahead: What’s Next for Stellest?
Essilor is pushing forward. The company is already expanding its Stellest 2.0 platform, which includes new plano (non-prescription) lenses designed to delay the onset of myopia in children at risk.³ Delaying the start of myopia can contribute significantly to better long-term eye health later in life.⁷
Final Thoughts
Myopia in children is not just a vision difference—it’s a growing global health challenge. With Essilor® Stellest® lenses, families now have access to a proven, FDA-authorized, non-invasive solution to help manage and slow down how fast nearsightedness progresses. Backed by strong clinical data and long-term research, Stellest offers hope and real impact: helping kids see today, but protecting how they see in the future.
If your child is nearsighted or at risk for myopia, talk to your optometrist about whether Stellest lenses might be a good fit for your family.
